poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).
Sponsors
GlaxoSmithKline Biologicals, Immunabs Inc., Fondazione Telethon Ets, San Raffaele Hospital
Conditions
Generalized Myasthenia Gravis and Ocular Myasthenia GravisInfectionsMeningococcalX-linked immunodeficiency with hyper-IgM type 1 (HIGM1)
Phase 1
A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine when Administered to Healthy Infants
CompletedCTIS2023-506449-40-00
Start: 2021-11-29End: 2025-11-21Target: 497Updated: 2025-09-01
A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Not yet recruitingCTIS2025-522406-20-00
Target: 51Updated: 2026-02-18
An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-based vector in Patients with X-linked Hyper IgM Syndrome Type 1 (HIGM1)
Not yet recruitingCTIS2025-524635-39-00
Target: 4Updated: 2026-05-20